Article thumbnail

Gut Microbiota and Inflammation

By Asa Hakansson and Goran Molin


Systemic and local inflammation in relation to the resident microbiota of the human gastro-intestinal (GI) tract and administration of probiotics are the main themes of the present review. The dominating taxa of the human GI tract and their potential for aggravating or suppressing inflammation are described. The review focuses on human trials with probiotics and does not include in vitro studies and animal experimental models. The applications of probiotics considered are systemic immune-modulation, the metabolic syndrome, liver injury, inflammatory bowel disease, colorectal cancer and radiation-induced enteritis. When the major genomic differences between different types of probiotics are taken into account, it is to be expected that the human body can respond differently to the different species and strains of probiotics. This fact is often neglected in discussions of the outcome of clinical trials with probiotics

Topics: Review
Publisher: MDPI
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2009). A core gut microbiome in obese and lean twins. Nature
  2. (2010). A human gut microbial gene catalogue established by metagenomic sequencing.
  3. (2002). A novel phenotype for an activated macrophage: The type 2 activated macrophage.
  4. (1996). A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive.
  5. (2009). A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy. Pediatr. Allergy Immunol.
  6. (2005). A prospective randomized trial of probiotics in critically ill patients.
  7. (2010). A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World
  8. (2005). A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm. Bowel Dis.
  9. (1989). A soluble Bacteroides by-product impairs phagocytic killing of Escherichia coli by neutrophils.
  10. (1995). Activated CD4+ and CD8+ cells in the colonic mucosa of ulcerative colitis patients: their relationship to HLA-DR antigen expression on the colonic epithelium and serum soluble CD25 levels. Digestion
  11. (1999). Active ageing makes the difference. Bull. World Health Organ.
  12. (1991). Acute effects of abdominopelvic irradiation on the orocecal transit time: Its relation to clinical symptoms, and bile salt and lactose
  13. (1983). Acute phase proteins with special reference to C-reactive and related proteins (pentaxins) and serum amyloid A protein.
  14. (2004). Alcohol and hepatocellular carcinoma. Gastroenterology
  15. (2010). Alcoholic liver disease and the gut-liver axis.
  16. (2011). Alcoholic liver disease: New insights into mechanisms and preventative strategies.
  17. Alternative activation of macrophages.
  18. (2005). Animal models simulating anaerobic infections. Anaerobe
  19. (2007). Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients.
  20. (2000). Antibody repertoire development in fetal and newborn piglets, III. Colonization of the gastrointestinal tract selectively diversifies the preimmune repertoire in mucosal lymphoid tissues. Immunology
  21. (2000). Antigen processing and presentation by intestinal epithelial cells—polarity and complexity.
  22. (2004). Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care
  23. (2004). Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes.
  24. (2002). Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis.
  25. (2001). Association between natural killer cell activity and infection in immunologically normal elderly people.
  26. (2006). Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut
  27. (2009). Bacterial community variation in human body habitats across space and time. Science
  28. (2009). Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One
  29. (2005). Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.
  30. Biologic therapies against inflammatory bowel disease: A dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
  31. (1995). Biological activity of Bacteroides lipopolysaccharide-reappraisal.
  32. (2001). CD4+CD25 high regulatory cells in human peripheral
  33. (2009). Cellular mediators of inflammation: Tregs and TH17 cells in gastrointestinal diseases. Mediators Inflamm.
  34. (1991). Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy.
  35. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes
  36. (1995). Cigarette smoking influences cytokine production and antioxidant defences.
  37. (2006). Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion. Immunobiology
  38. (2003). Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation
  39. Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel disease.
  40. (2007). Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy.
  41. (1994). Clinical significance of translocation. Gut
  42. (1917). Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle
  43. (1996). Colonic mucins in ulcerative colitis: Evidence for loss of sulphation.
  44. (2002). Commensal associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal
  45. (2005). Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes.
  46. (2000). Cutting edge: Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway.
  47. (1999). Cytokines in alcoholic liver disease. Semin. Liver Dis.
  48. (1995). Decreased immunity and increased morbidity in the elderly.
  49. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria.
  50. (1998). Development and maintenance of the gut-associated lymphoid tissue (GALT): The roles of enteric bacteria and viruses.
  51. (2000). Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease.
  52. (2006). Differential release and distribution of
  53. (2009). Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis.
  54. (2005). DNA-based classification and sequence heterogeneities in the 16S rRNA genes of Lactobacillus casei/paracasei and related species.
  55. (2002). Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: A controlled trial in liver transplant recipients. Transplantation
  56. (1987). Effect of irradiation on morphology and motility of canine small intestine.
  57. (2011). Effect of lactobacilli on paracellular permeability in the gut. Nutrients
  58. (2002). Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers.
  59. (2008). Effect of Lactobacillus plantarum enteral feeding on the gut permeability and septic complications in the patients with acute pancreatitis.
  60. (2008). Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis.
  61. (2010). Effect of viable Bifidobacterium supplement on the immune status and inflammatory response in patients undergoing resection for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi
  62. (2008). Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants.
  63. (2008). Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial.
  64. (2004). Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World
  65. (2007). Effects of probiotic therapy in critically ill patients: A randomized, double-blind, placebo-controlled trial.
  66. Effects of radiation on the human gastrointestinal tract.
  67. (2006). Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
  68. (1999). Elevated C-reactive protein levels in overweight and obese adults. JAMA
  69. (1977). Endotoxin and bacteria in portal blood. Gastroenterology
  70. (2004). Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis. Drug Metab. Dispos.
  71. (1999). Endotoxin-tolerant mice have mutations in Toll-like receptor 4
  72. (2001). Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019.
  73. (2007). Environmental shotgun sequencing: Its potential and challenges for studying the hidden world of microbes. PLoS Biol.
  74. (1997). Evidence of the proinflammatory role of Enterococcus faecalis in polymicrobial peritonitis in rats.
  75. (2009). Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease.
  76. (1993). Expansion of alpha beta T cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. Immunology
  77. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. PNAS
  78. (1987). Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA
  79. (2007). FOXP3 mRNA expression at 6 months of age is higher in infants who develop atopic dermatitis, but is not affected by giving probiotics from birth. Pediatr. Allergy Immunol.
  80. (1985). Free-radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect.
  81. (1993). Gastrointestinal function in chronic radiation enteritis—effects of loperamide-N-oxide. Gut
  82. (2009). Global diversity in the human salivary microbiome. Genome Res.
  83. Guidelines for the Evaluation of Probiotics in Food; Joint FAO/WHO Working Group Report,
  84. (2007). Gut microbiota composition and development of atopic manifestations in infancy: The KOALA Birth Cohort Study. Gut
  85. (1999). Gut-associated Lymphoid Tissue. Regulation of IgA B-cell Development. In Mucosal Immunology;
  86. (1999). Gut-associated lymphoid tissues in ulcerative colitis.
  87. (2002). Gut-liver axis: A new point of attack to treat chronic liver damage?
  88. (2000). Gut-liver axis.
  89. (2007). Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury.
  90. (1987). Hepatobiliary complications of inflammatory bowel disease.
  91. (2007). High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut
  92. (2007). High proportions of proinflammatory bacteria on the colonic mucosa in a young patient with ulcerative colitis as revealed by cloning and sequencing of 16S rRNA genes.
  93. (2007). High-dose probiotics for the treatment of active pouchitis. Dis. Colon Rectum
  94. (1989). Human endothelial cell adhesiveness of neutrophils, induced by Escherichia coli lipopolysaccharide in vitro, is inhibited by Bacteroides fragilis lipopolysaccharide.
  95. (2009). Human gut microbiota in obesity and after gastric bypass. PNAS
  96. (2007). Immune dysfunction in inflammatory bowel disease.
  97. (2010). Immunomodulation by commensal and probiotic bacteria.
  98. (1993). Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion
  99. (2006). Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: A randomised, double blind, placebo controlled GETAID trial. Gut
  100. (2002). Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: A randomised controlled trial with Lactobacillus GG. Gut
  101. (2009). Inflammation in the intestinal tract: Pathogenesis and treatment.
  102. (2008). Inflammatory Bowel Disease.
  103. (2002). Influence of portal pressure change on intestinal permeability in patients with portal hypertension.
  104. (2001). Innate immune responses of epithelial cells following infection with bacterial pathogens.
  105. (2006). Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota.
  106. (2003). Interpretation of circulating C-reactive protein levels in adults: Body mass index and gender are a must. Diabetes Metab.
  107. (1987). Interrelations between mucosal and luminal microflora of gastrointestine. Nahrung
  108. (2010). Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe
  109. (1996). Intestinal inflammation in children with atopic eczema: Faecal eosinophil cationic protein and tumour necrosis factor-alpha as non-invasive indicators of food allergy.
  110. (2010). Intestinal Lactobacillus sp. is associated with some cellular and metabolic characteristics of blood in elderly people. Anaerobe
  111. (2001). Is bacterial ash the flash that ignites NASH? Gut
  112. (2000). Is Lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study.
  113. (1977). Isolation and identification of encapsulated strains of Bacteroides fragilis.
  114. (1966). Lactobacillus acidophilus (Enpac) in treatment of hepatic encephalopathy.
  115. (2008). Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp. lactis DGCC 420 modulate unspecific cellular immune response in healthy adults.
  116. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease.
  117. (2008). Lactobacillus plantarum 299v reduces colonization of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol. Scand.
  118. (2007). Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: A randomised study.
  119. (1999). Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways.
  120. (2009). Liver architecture, cell function, and disease.
  121. (2002). Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol.
  122. (2005). Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy
  123. (2002). Markers of inflammation in the feces of infants with cow’s milk allergy. Pediatr. Allergy Immunol.
  124. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes
  125. (2009). Metagenomic study of the oral microbiota by Illumina high-throughput sequencing.
  126. (1996). Microbial colonization influences composition and T cell receptor V beta repertoire of intraepithelial lymphocytes in rat intestine. Immunology
  127. (2006). Microbial ecology: Human gut microbes associated with obesity. Nature
  128. (2004). Microbial gut interactions in health and disease. Immune responses.
  129. (1976). Microbial synergy in experimental intra-abdominal abscess.
  130. (2008). Microbiome project seeks to understand human body’s microscopic residents. JAMA
  131. (2005). Molecular analysis of jejunal, ileal, caecal and rectosigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism.
  132. (1998). Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products.
  133. (1996). Molecular biological evidence for the occurrence of uncultured members of the actinomycete line of descent in different environments and geographical locations.
  134. (2002). Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces.
  135. (2002). Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls.
  136. (2000). Mucosal cytokine production in radiation induced proctosigmoiditis compared with inflammatory bowel disease.
  137. (2002). Mucosal flora in inflammatory bowel disease. Gastroenterology
  138. (2007). Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm. Bowel Dis.
  139. No causal link between obesity and probiotics.
  140. NOD-like receptors: role in innate immunity and inflammatory disease.
  141. (2003). Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science
  142. (2002). Nonalcoholic fatty liver disease: An agenda for clinical research. Hepatology
  143. (2002). Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis.
  144. (2008). Novel microarray design strategy to study complex bacterial communities.
  145. (2001). Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis.
  146. (2008). Obesity pandemics and the modification of digestive bacterial flora.
  147. (2008). On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials.
  148. (2005). Organizing a mucosal defence.
  149. (1986). Pathologic changes secondary to radiation.
  150. (1999). Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2.
  151. (2005). Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease. Gastroenterology
  152. (1997). Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ. Health Perspect.
  153. (1994). Pouchitis following ileal pouch-anal anastomosis: Definition, pathogenesis, and treatment. Gastroenterology
  154. (2008). Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to
  155. (1988). Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures.
  156. (2008). Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis.
  157. (1998). Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects.
  158. (2005). Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatr. Allergy Immunol.
  159. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. Lancet
  160. (2008). Probiotic yogurt for the treatment of minimal hepatic encephalopathy.
  161. Probiotics and obesity: A link?
  162. (2008). Probiotics for induction of remission in Crohn’s disease.
  163. (2007). Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.
  164. (2001). Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet
  165. (2000). Probiotics in the management of atopic eczema.
  166. (2008). Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: A pilot study. Alcohol
  167. Probiotics—little evidence for a link to obesity.
  168. (1965). Probiotics: Growth promoting factors produced by microorganisms. Science
  169. (2004). Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.
  170. (2004). Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxiemia in alcoholic liver disease.
  171. (2008). Reduced diversity in the early fecal microbiota of infants with atopic eczema.
  172. (2004). Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut
  173. (2010). Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier.
  174. (1988). Regulation of IgA secretion by T cell clones derived from the human gastrointestinal tract.
  175. (2009). Regulatory lymphocytes and intestinal inflammation.
  176. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps.
  177. (2010). Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World
  178. (2002). Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signalling.
  179. (2001). Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea.
  180. (1981). reticuloendothelial function and liver injury. Hepatology
  181. (2005). Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis.
  182. (2001). Role of P-selectin in radiation-induced intestinal inflammatory damage.
  183. (2004). Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology
  184. (1998). Significant decrease in fibrinogen and LDL-cholesterol levels upon supplementation of the diet with Lactobacillus plantarum (ProViva) in subjects with moderately elevated cholesterol concentrations. Atherosclerosis
  185. (2005). Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease.
  186. (2009). Specific probiotics alleviate allergic rhinitis during the birch pollen season. World
  187. (2004). Starting at the beginning: new perspectives on the biology of mucosal T cells.
  188. (2007). Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis.
  189. (1990). Structure-activity relationships in lipopolysaccharides of Bacteroides fragilis.
  190. (2009). Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis.
  191. (2005). Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation—a randomized, double-blind
  192. (2006). Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science
  193. (2004). Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology
  194. (2000). Synergy of Bacteroides fragilis and Escherichia coli in the induction of KC gene expression in mouse peritoneal tissues.
  195. (2007). Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis.
  196. (2008). The biology of intestinal immunoglobulin A responses. Immunity
  197. (1979). The clearance, tissue distribution and cellular localization of intravenously injected lipopolysaccharide in rabbits.
  198. (2000). The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut
  199. (2001). The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation.
  200. (2008). The Foxp3+ regulatory T cell: A jack of all trades, master of regulation.
  201. (2004). The gut microbiota as an environmental factor that regulates fat storage.
  202. (2008). The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention.
  203. (2008). The inflammatory status of old age can be nurtured from the intestinal environment.
  204. (2006). The liver as an immunological organ. Hepatology
  205. (2003). The many faces of macrophage activation.
  206. (2003). The Mucosa-Associated Bacteria from the Sigmoid Colon of Nine Healthy 60-Year-Old Individuals, Identified by Bacterial 16S rDNA;
  207. (1994). The phylogeny of the genus Clostridium: Proposal of five new genera and eleven new species combinations.
  208. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.
  209. (1907). The Prolongation of Life;
  210. (1990). The role of bacterial failure and bacterial translocation in the development of systemic infection and multiple organ failure.
  211. (1984). The role of granulocytes in inflammation.
  212. (2005). The role of gut-associated lymphoid tissues and mucosal
  213. (2001). The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut
  214. (2009). The structurally similar, penta-acylated lipopolysaccharides of Porphyromonas gingivalis and Bacteroides elicit strikingly different innate immune responses.
  215. (1994). Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut
  216. (2010). Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One
  217. (2002). Tissue expression of human Tolllike receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.
  218. (2002). TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells.
  219. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis.
  220. (2009). Toll-like receptors and their role in gastrointestinal disease.
  221. (2009). Toll-like receptors as targets in chronic liver diseases. Gut
  222. (2001). Toll-like receptors: Critical proteins linking innate and acquired
  223. (2009). Towards the human intestinal microbiota phylogenetic core.
  224. (1979). Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model.
  225. (1965). Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus. Lancet
  226. (2004). Ulcerative colitis practice guidelines in adults.
  227. (2002). Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis.
  228. (1977). Ultrastructure of Butyrivibrio fibrisolvens: A gram-positive bacterium?
  229. (1981). Uptake by liver cells of endotoxin following its intravenous injection.
  230. (2002). Use of Lactobacillus-GG in paediatric Crohn’s disease. Dig. Liver Dis.
  231. (2007). Use of probiotics for prevention of radiation-induced diarrhea.
  232. (2005). VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.